A Phase 1, Single dose Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Healthy Volunteers

Exclusion Criteria

• -Any concurrent condition that in the opinion of the investigator would interfere with the evaluation of the investigational product
• -History or presence of gastrointestinal, renal, or hepatic disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs
• -History of cancer, with the exception of non-melanoma skin cancer
• -Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks prior to dosing
• -Positive Hepatitis B, Hepatitis C or HIV test or use of antiretroviral medications at screening.
• -Concurrent or previous use of a GLP-1 receptor agonist
• -Current or previous use of systemic corticosteroids within the past 28 days prior to screening
• -Use of any medicinal products or herbal preparations licensed for control of body weight or appetite is prohibited.
• -Known or suspected history of alcohol or drug abuse within the past 3 years.
• -Positive drug screen
• -Current smoker